Osteoprotegerin and 25-hydroxy vitamin D levels in patients with diabetic foot

Objective & Hypothesis:Objectives: This study aims to compare the levels of osteoprotegerin (OPG) and 25-hydroxy vitamin D (25(OH)D) in patients with diabetic foot and patients with newly diagnosed type 2 diabetes mellitus (DM) and to investigate the prevalence and severity of 25(OH)D insufficiency in patients with diabetic foot.

📊

Key Findings & Data:Patients and methods: This prospective study was conducted on 105 patients including 58 patients with diabetic foot (42 males, 16 females; mean age 63.6 years; range, 31 to 90 years), who applied to our hospital between June 2014 and May 2015, and 47 newly diagnosed type 2 DM patients (27 males, 20 females; mean age 51.4 years; range, 29 to 85 years) (control group). 25(OH)D and osteoprotegerin serum levels in both groups were measured and compared.

💡

Conclusion & Impact:Results: Osteoprotegerin levels in diabetic foot group were significantly higher than the control group (p

🔬Design:Research Article

📍Scope:2014 Verileri

⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to compare the levels of osteoprotegerin (OPG) and 25-hydroxy vitamin D (25(OH)D) in patients with diabetic foot and patients with newly diagnosed type 2 diabetes mellitus (DM) and to investigate the prevalence and severity of 25(OH)D insufficiency in patients with diabetic foot. Patients and methods: This prospective study was conducted on 105 patients including 58 patients with diabetic foot (42 males, 16 females; mean age 63.6 years; range, 31 to 90 years), who applied to our hospital between June 2014 and May 2015, and 47 newly diagnosed type 2 DM patients (27 males, 20 females; mean age 51.4 years; range, 29 to 85 years) (control group). 25(OH)D and osteoprotegerin serum levels in both groups were measured and compared. Results: Osteoprotegerin levels in diabetic foot group were significantly higher than the control group (p

Özet

Amaç: Bu çalışmada diyabetik ayaklı hastalarda ve yeni tanı konulmuş tip 2 diabetes mellitus (DM)’lu hastalarda osteoprotegerin (OPG) ve 25-hidroksi D vitamini (25(OH)D) düzeyleri karşılaştırıldı ve diyabetik ayaklı hastalarda 25(OH)D eksikliğinin yaygınlığı ve şiddeti araştırıldı. Hastalar ve yöntemler: Bu ileriye dönük çalışma Haziran 2014 ve Mayıs 2015 tarihleri arasında hastanemize başvuran 58 diyabetik ayaklı hasta (42 erkek, 16 kadın; ort. yaş 63.6 yıl; dağılım, 31-90 yıl) ve 47 yeni tanı konulmuş tip 2 DM’li hasta (27 erkek, 20 kadın; ort. yaş 51.4 yıl; dağılım, 29-85 yıl) (kontrol grubu) olmak üzere 105 hasta üzerinde gerçekleştirildi. Her iki grupta 25(OH)D ve OPG serum düzeyleri ölçüldü ve karşılaştırıldı. Bulgular: Diyabetik ayak grubunda OPG düzeyleri kontrol grubundan anlamlı olarak daha yüksekti (p

🔖

Cite This Article

PİLTEN, S., ÇAĞLAR, S., BEYTEMUR, O., ÇAĞLAR, A., ALBAY, C., SARI, H. (2022). Osteoprotegerin and 25-hydroxy vitamin D levels in patients with diabetic foot. Eklem Hastalıkları ve Cerrahisi Dergisi (Eski Adı: Artroplasti Artroskopik Cerrahi Derg.), Cilt: 29 - Sayı: 3, 170–175. https://ajindex.com/articles/498422

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Rasmussen LM, Ledet T. Osteoprotegerin and diabetic macroangiopathy. Horm Metab Res 2005;37:90-4.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
Fu M, Zhang J, Lin Yg Yg, Zhu X, Willson TM, Chen YE. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem Biophys Res Commun 2002;294:597-601.
Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002;521:180-4.
Ovchinnikova O, Gylfe A, Bailey L, Nordström A, Rudling M, Jung C, et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoEdeficient mice--brief report. Arterioscler Thromb Vasc Biol 2009;29:1478-80.
Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008;117:411-20.
Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005;182:175-80.
Baeke F, Etten EV, Overbergh L, Mathieu C. Vitamin D3 and the immune system: maintaining the balance in health and disease. Nutr Res Rev 2007;20:106-18.
Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004;80:1717-20.
Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004;79:820-5.
Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000;374:334-8.
Kawarau A, Takeda E, Tanida N, Nakagawa K, Yamamoto H. Inhibitory effect of long term 1-alpha-hydroxyvitamin D3 administration on Helicobacter pylori infection. J Clin Biochem Nutr 2006;38:103-6.
Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One 2010;5:11088. Tiwari S, Pratyush DD, Gupta B. Prevalence and severity of vitamin D deficiency in patients with diabetic foot infection. Br J Nutr 2013;109:99-102. Atik OŞ. Are all case reports worth publishing? Eklem Hastalik Cerrahisi 2016;27:61. Sz